Cervical cancer working group report

Japanese Journal of Clinical Oncology

Volumn 40, Issue SUPPL. 1, 2010, Pages

  Konno, Ryo ^a   Sagae, Satoru ^b   Yoshikawa, Hiroyuki ^c   Basu, Partha Sarathi ^d   Hanley, Sharon J B ^e   Tan, Jeffrey H J ^f   Shin, Hai Rim ^g  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b JR Sapporo Hospital   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^e Department of Health Sciences   (Japan)

^f ROYAL WOMEN'S HOSPITAL   (Australia)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervical cancer; Human papillomavirus; Prevention; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; AUSTRALIA; CANCER CONTROL; CANCER SCREENING; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; INCIDENCE; INDIA; JAPAN; UNITED KINGDOM; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; ADULT; ASIA; CHILD; FEMALE; PAPILLOMAVIRUS INFECTION; UTERINE CERVICAL NEOPLASMS;

ADULT; ASIA; CHILD; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 77957280128     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq126     Document Type: Article

References (26)

1. Vaccarella S, Franceschi S, Snijders PJF, Herrero R, Meijer CJLM, Plummer M. IARC HPV Prevalence Surveys Study Group. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2010;19:503-10.
2. Bouvard V, Baan R, Straif K, Freeman C, Galichet L, Cogliano V, et al., WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10:321-2.
3. Shin HR, Masuyer E, Ferlay J, Maria-Paula Curado MP, on behalf of the Asian Contributors to CI5 IX. Cancer in Asia incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev 2010;11(Suppl. 2):11-16.
4. http://www-dep.iarc.fr/GLOBOCAN/2008.
5. Chung HH, Jang MJ, Jung KW, Shin HR, Kim JW, Lee HP, et al., Members for Gynecologic Oncology Committee of Korean Society of Obstetrics and Gynecology. Cervical cancer incidence and survival in Korea: 1993-2002. Int J Gynecol Cancer 2006;16:1833-8.
6. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-76.
7. Oh JK, Lim MK, Yun EH, Lee EH, Shin HR. Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey. Vaccine 2010;28:1854-60.
8. Konno R, Shin HR, Kim YT, Song YS, Sasagawa T, Inoue M, et al. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine 2008;26(Suppl 12):M30-42.
9. Armesto Garcia S, Lapetra Gil ML, Wei L, Kelley E, Members of the Health Care Quality Indicators (HCQI) Expert Group. Health Care Quality Indicators Project 2006 Data Collection Update Report. OECD HealthWorking Papers No. 29, DELSA/HEA/WD/HWP. Paris: Organization for Economic Co-operation and Development; 2007.
10. Onuki M, Matsumoto K, Satoh T, Yamada N, Hamada H, Yoshikawa H, et al. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009;100:1312-6.
11. Konno R, Sasagawa T, Fukuda T, Van-Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010;20:385-92.
12. Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, et al. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2008;26(Suppl 12):M89-98.
13. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-about.
14. http://www.aihw.gov.au/publications/can/can-43-10676/can-43-10676.pdf.
15. http://www.cancervic.org.au/images/research/CEC/CervicalCancer/CervicalCancer2006.pdf.
16. http://www.aph.gov.au/library/pubs/BD/2007-08/08bd007.htm.
17. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Austraila. Commun Dis Intell 2008;32:457-61.
18. http://www.hpvregister.org.au/.
19. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008;123:1854-63.
20. http://www.cancerscreening.nhs.uk/cervical/(30 October 2009, date last accessed).
21. http://ganjoho.ncc.go.jp/professional/statistics/statistics.html (1 November 2009, date last accessed).
22. http://www.isdscotland.org/isd/6153.html (2 November 2009, date last accessed).
23. http://www.fightcervicalcancer.org.uk/(5 November 2009, date last accessed).
24. World Health Organization. WHO position on HPV vaccines. Vaccine 2009;27:7236-7.
25. Paavonen J, Naud P, Salmerón J, Struyf F, Lehtinen M, Dubin G, et al., HPV PATRICIA Study Group, Greenacre M. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
26. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M-H, et al. Overview of the evidence from cervical cancer screening studies. Vaccine 2008;26(Suppl 10):K29-41.